CoreCap Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

CoreCap Advisors’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72K	Hold	41	–	–	﹤0.01%	2460
2026 Q1	$2.22K	Hold	41	–	–	﹤0.01%	2387
2025 Q4	$2.3K	Hold	41	–	–	﹤0.01%	2445
2025 Q3	$1.97K	Hold	41	–	–	﹤0.01%	2380
2025 Q2	$1.66K	Hold	41	–	–	﹤0.01%	2345
2025 Q1	$1.8K	Hold	41	–	–	﹤0.01%	2384
2024 Q4	$1.76K	Sell	41 -32	-44%	-$1.46K	﹤0.01%	2265
2024 Q3	$3.24K	Sell	73 -13	-15%	-$557	﹤0.01%	2083
2024 Q2	$3.42K	Sell	86 -23	-21%	-$932	﹤0.01%	1226
2024 Q1	$4.7K	Buy	+109	New	+$4.7K	﹤0.01%	1933
2022 Q4	$20.4K	Buy	+499	New	+$20.8K	﹤0.01%	1294
2022 Q3	–	Sell	-585	Closed	-$25K	–	2137
2022 Q2	$25K	Buy	+585	New	+$24.5K	﹤0.01%	1173
2022 Q1	–	Sell	-4	Closed	-$1K	–	2134
2021 Q4	$1K	Buy	+4	New	+$190	﹤0.01%	2291

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CoreCap Advisors's XPH Position: Q2 2026 in Review

CoreCap Advisors held its State Street SPDR S&P Pharmaceuticals ETF (XPH) position steady in Q2 2026 at 41 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

CoreCap Advisors first reported a position in XPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $25K in Q2 2022. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

CoreCap Advisors held 41 shares of State Street SPDR S&P Pharmaceuticals ETF worth $2.72K as of Q2 2026.
CoreCap Advisors left its State Street SPDR S&P Pharmaceuticals ETF share count unchanged in Q2 2026.
State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2460 holding.
CoreCap Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2021 and has held it in 13 quarters since.
CoreCap Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $25K in Q2 2022.
93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.